You are here

Article Text

Article menu
PDF
PostScript
Correspondences
Hypertrophic cardiomyopathy and the potential influence of etomidate on postoperative outcomes
  1. Leigh David White1,2,
  2. Ruan Vlok3,
  3. Calum Chong4,
  4. Thomas M Melhuish4
  1. 1Faculty of Science Medicine and Health, University of Wollongong, Graduate School of Medicine, Wollongong, New South Wales, Australia
  2. 2Wagga Wagga Base Hospital, Wagga Wagga, New South Wales, Australia
  3. 3University of Notre Dame Australia, Fremantle, New South Wales, Australia
  4. 4University of New South Wales, Sydney, New South Wales, Australia
  1. Correspondence to Dr Leigh David White, Faculty of Science Medicine and Health, University of Wollongong, Graduate School of Medicine, Wollongong, NSW 2522, Australia; lw844{at}uowmail.edu.au

http://dx.doi.org/10.1136/heartjnl-2016-310454

Statistics from Altmetric.com

    To the Editor,

    We read with interest the paper by Dhillon and colleagues1 which provided a high-quality propensity-matched observational study of perioperative outcomes in patients with hypertrophic cardiomyopathy (HCM). This study showed no difference in what they defined as ‘hard outcomes’ such as myocardial infarction, stroke and death. They did however show an increased incidence of composite end …

    View Full Text

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

    Linked Articles